682 related articles for article (PubMed ID: 31759375)
41. Study of the association between five polymorphisms and risk of hepatocellular carcinoma: A meta-analysis.
Yu JY; Hu F; Du W; Ma XL; Yuan K
J Chin Med Assoc; 2017 Apr; 80(4):191-203. PubMed ID: 28188097
[TBL] [Abstract][Full Text] [Related]
42. Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients.
Elemeery MN; Badr AN; Mohamed MA; Ghareeb DA
World J Gastroenterol; 2017 Jun; 23(21):3864-3875. PubMed ID: 28638226
[TBL] [Abstract][Full Text] [Related]
43. Association of Polymorphism in Survivin Gene and the Risk of Liver Cancer Resulting from Hepatitis C Virus Among Egyptian Patients.
Mohamed AA; Yassin AS; Gomaa BS; Darwish H; Mohamed RS; Makled S; Ramdan A; Abd-Elsalam S; Raafat MM
Curr Cancer Drug Targets; 2021; 21(6):536-543. PubMed ID: 33653251
[TBL] [Abstract][Full Text] [Related]
44. Association of a potential functional pre-miR-218 polymorphism and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk.
Han Y; Pu R; Han X; Zhao J; Li W; Yin J; Zhang Y; Shen Q; Xie J; Zhang Q; Jiang S; Li J; Zhang H; Wang H; Cao G
Liver Int; 2014 May; 34(5):728-36. PubMed ID: 24118778
[TBL] [Abstract][Full Text] [Related]
45. Functional miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms and the susceptibility to hepatocellular carcinoma: An updated meta-analysis.
Zheng L; Zhuang C; Zhao J; Ming L
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):664-676. PubMed ID: 28499985
[TBL] [Abstract][Full Text] [Related]
46. Association between microRNA-196A2 and microRNA-146A polymorphisms and progression to cirrhosis and hepatocellular carcinoma in patients with viral hepatitis B.
Riazalhosseini B; Mohamed Z; Apalasamy YD; Eng HS; Mohamed R
Pharmacogenet Genomics; 2016 Feb; 26(2):74-9. PubMed ID: 26529280
[TBL] [Abstract][Full Text] [Related]
47. Association of genetic variants in the interleukin-18 gene promoter with risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus infection.
Bakr NM; Awad A; A Moustafa E
IUBMB Life; 2018 Feb; 70(2):165-174. PubMed ID: 29341496
[TBL] [Abstract][Full Text] [Related]
48. Study of Toll-like Receptor 3 Gene Polymorphism as a Novel Risk Factor for HCV-related Hepatocellular Carcinoma in Egypt.
El-Sharawy S; Negm OE; Abd-Elsalam S; El-Sorogy HA; Shehata MAH
Curr Cancer Drug Targets; 2020; 20(5):382-389. PubMed ID: 32189594
[TBL] [Abstract][Full Text] [Related]
49. Role of
Barooah P; Saikia S; Bharadwaj R; Sarmah P; Bhattacharyya M; Goswami B; Medhi S
Genet Test Mol Biomarkers; 2019 May; 23(5):325-331. PubMed ID: 30942619
[No Abstract] [Full Text] [Related]
50. Serum PAI-1 and PAI-1 4G/5G Polymorphism in Hepatitis C Virus-Induced Cirrhosis and Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients.
El Edel RH; Essa ES; Essa AS; Hegazy SA; El Rowedy DI
Viral Immunol; 2016 Nov; 29(9):510-515. PubMed ID: 27459171
[TBL] [Abstract][Full Text] [Related]
51. Genetic polymorphism of IL-23R influences susceptibility to HCV-related hepatocellular carcinoma.
Labib HA; Ahmed HS; Shalaby SM; Wahab EA; Hamed EF
Cell Immunol; 2015 Mar; 294(1):21-4. PubMed ID: 25666505
[TBL] [Abstract][Full Text] [Related]
52. Matrix Metalloproteinase-11 Gene Polymorphisms as a Risk for Hepatocellular Carcinoma Development in Egyptian Patients.
Saad H; Zahran MA; Hendy O; Abdel-Samiee M; Bedair HM; Abdelsameea E
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3725-3734. PubMed ID: 33369474
[TBL] [Abstract][Full Text] [Related]
53. Ghrelin gene polymorphism as a genetic biomarker for prediction of therapy induced clearance in Egyptian chronic HCV patients.
Hamdy M; Kassim SK; Khairy E; Maher M; Mansour KA; Albreedy AM
Gene; 2018 Apr; 649():74-79. PubMed ID: 29374597
[TBL] [Abstract][Full Text] [Related]
54. Effect of CD133 polymorphisms on the risk of developing liver cirrhosis and hepatocellular carcinoma induced by viral hepatitis.
Hassan M; Nasr SM; Elzallat M
Virus Res; 2022 Apr; 312():198714. PubMed ID: 35181408
[TBL] [Abstract][Full Text] [Related]
55. The MTHFR C677T mutation is not a risk factor recognized for HBV-related HCC in a population with a high prevalence of this genetic marker.
Jiao X; Luo Y; Yang B; Jing L; Li Y; Liu C; Jing X; Wang F; Wang Y; Du Z; Gao Y
Infect Genet Evol; 2017 Apr; 49():66-72. PubMed ID: 28082187
[TBL] [Abstract][Full Text] [Related]
56. Association of Interleukin-8 Gene Polymorphisms and Expression with Hepatocellular Carcinoma in Egyptian Patients with Liver Cirrhosis.
Hassanin OM; El-Masry TM; El-Baz A; Adel-Abou-Zaghla HM
Egypt J Immunol; 2017 Jan; 24(1):143-152. PubMed ID: 29120586
[TBL] [Abstract][Full Text] [Related]
57. The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients.
Mohamed AA; Esmail OE; Ibrahim AMA; Makled S; Al-Hussain E; Elsaid A; Alboraie M; El-Awady RR
J Med Virol; 2023 Jan; 95(1):e28343. PubMed ID: 36424348
[TBL] [Abstract][Full Text] [Related]
58. miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma.
Shaker O; Alhelf M; Morcos G; Elsharkawy A
Infect Genet Evol; 2017 Jul; 51():173-181. PubMed ID: 28366737
[TBL] [Abstract][Full Text] [Related]
59. Association of genetic polymorphism of BCL-2 (rs2279115) with susceptibility to HCV-related hepatocellular carcinoma.
Ahmed HS; Wahab EA; Elhady HA; Elgerby MM
Immunol Res; 2020 Aug; 68(4):189-197. PubMed ID: 32623689
[TBL] [Abstract][Full Text] [Related]
60. The interaction between microRNA-152 and DNA methyltransferase-1 as an epigenetic prognostic biomarker in HCV-induced liver cirrhosis and HCC patients.
El-Araby RE; Khalifa MA; Zoheiry MM; Zahran MY; Rady MI; Ibrahim RA; El-Talkawy MD; Essawy FM
Cancer Gene Ther; 2020 Jun; 27(6):486-497. PubMed ID: 31316135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
